Scholar Rock Holding Corporation
- SRRK
- NASDAQ
- Biotechnology
- Growth Factor Inhibitors
- Neuromuscular Disease (SMA)
$40.24
Today +0.85%Quote Oct 19, 2026, 08:00 PM UTC
−13.74%over the last month
Max drawdown −22.6%From 1-month high −21.4%3 months −20.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Scholar Rock
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA).
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
289
Market value
$4.90B
Quote Oct 19
Floor
$39.81
1.1% below price
Resistance
$43.46
8.0% above price
Price vs analyst targets
14 analysts
Lowest target
$58.00Highest target
$84.00
$58.00Highest target
$84.00
- Price $40.24
- Average target $70.45
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 75% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about SRRKPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free